P Pharming Group NV
P
Chiusa
1.1 -2.57
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
1.096
Massimo
1.133
Entrata | -10M -5.1M |
|---|---|
Vendite | -36M 71M |
P/E Media del settore | 55.3 51.415 |
EPS | 0.01 |
Margine di Profitto | -7.196 |
Dipendenti | 407 |
EBITDA | -4.8M -2.1M |
Utili prossimi | 30 lug 2026 |
|---|
Capitalizzazione di Mercato | -227M 781M |
|---|---|
Apertura precedente | 3.67 |
Chiusura precedente | 1.1 |
Pharming Group NV Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Pharming Group NV Previsione
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
